General Announcement::GPL enters into an exclusive licensing agreement to commercialize generic Tiotropium Bromide

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
29-Aug-2018 11:24:05
Status
New
Announcement Sub Title
GPL enters into an exclusive licensing agreement to commercialize generic Tiotropium Bromide
Announcement Reference
SG180829OTHR5UQZ
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
29/08/2018 08:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark enters into an exclusive licensing agreement to commercialize generic Tiotropium Bromide dry powder inhaler in Western Europe

Attachments

PR_29082018.pdf
Total size =3275K